Vertex (VRTX) Orkambi 6-11 Launch Tracking Similar to Adult Launch - Jefferies

November 14, 2016 8:22 AM EST
Get Alerts VRTX Hot Sheet
Price: $81.37 +0.57%

Rating Summary:
    24 Buy, 17 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VRTX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst Brian Abrahams reiterated a Buy rating and $102 price target on Vertex (NASDAQ: VRTX), saying Orkambi 6-11 launch tracking similar to adult launch.

Abrahams commented, "Based on our analysis of Rx trends, it looks like since label expansion Orkambi prescriptions are being written for 6-11 year olds at the same pace, relative to the number of homozygous CF pts in each age bracket, as it was for adults when it was first launched. Though there are some limitations to interpreting the data, overall we view this as a favorable in-line trend and continue to believe uptake and persistence in this group will be solid."

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $92.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Jefferies & Co

Add Your Comment